Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)

This study has been completed.
Sponsor:
Information provided by:
Technische Universität Dresden
ClinicalTrials.gov Identifier:
NCT00422890
First received: January 15, 2007
Last updated: July 8, 2011
Last verified: July 2011
  Purpose

Efficacy and safety of 5-Azacytidin in the treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with falling CD34-chimerism after hematopoietic stem cell transplantation.


Condition Intervention Phase
Myeloid Leukemia
Myelodysplastic Syndrome
Drug: 5-Azacytidin
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Technische Universität Dresden:

Primary Outcome Measures:
  • Efficacy of 5-Azacytidin in the treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with falling CD34-chimerism after hematopoietic stem cell transplantation. [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Safety of 5-Azacytidin in the treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with falling CD34-chimerism after hematopoietic stem cell transplantation. [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 10
Study Start Date: January 2007
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: 5-Azacytidin
    in case of decreasing CD34 chimerism
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Screening phase:

  • Age > 18 years
  • Patients with CD34+ AML or MDS post-allogeneic HSCT
  • Written patient consent after consultation

Treatment phase

  • AML/MDS: donor chimerism < 80% in the CD34+ subpopulation following allogeneic HSCT in patients with CD34+ AML or MDS, but with no haematological relapse (blasts < 5% in bone marrow)
  • Leukocytes > 3 Gpt/l and platelets > 75 Gpt/l (transfusion-independent)

Exclusion Criteria:

  • Known intolerance to 5-azacitidine or mannitol
  • Uncontrollable infectious disease
  • Patients with active hepatitis B or C or HIV infection
  • Severe hepatic function impairment (ASAT and ALAT may not be above three times the normal value) or hepatic cirrhosis, or malignant hepatic tumour
  • Renal function impairment (creatinine > twice the normal value, creatinine clearance < 50 ml/min)
  • Pregnancy or lactation
  • Women of childbearing age, except for those who meet the following criteria:
  • postmenopausal (12 months natural amenorrhoea)
  • postoperative (6 weeks after bilateral ovarectomy with or without hysterectomy)
  • regular and correct use of a contraceptive method with an error rate < 1% per year (e.g. implants, depot injections, combined oral contraceptives, intrauterine device - IUD, whereby hormonal coils with a Pearl Index of < 1% are safer than copper coils)
  • sexual abstinence
  • Partner vasectomy
  • Men who do not use one of the following for contraception:
  • sexual abstinence
  • post vasectomy
  • condoms
  • Participation of the patient in a drug trial outside the indication of allogeneic transplantation up to four weeks before study initiation
  • Addictive or other illnesses that prevent the person concerned from comprehending the nature and impact, as well as potentical consequences of the clinical trial
  • Evidence that the patient may intentionally not comply with the protocol, e.g. lack of cooperation With the exception of a known allergic reaction or intolerance to 5-azacitidine, these criteria do not apply to the screening phase.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00422890

Locations
Germany
University hospital Dresden, department of medicine
Dresden, Saxony, Germany, 01307
Sponsors and Collaborators
Technische Universität Dresden
Investigators
Principal Investigator: Uwe Platzbecker, MD Univesity Hospital Dresden, department of medicine
  More Information

No publications provided

Responsible Party: MD Uwe Platzbecker, Dresden University of Technology
ClinicalTrials.gov Identifier: NCT00422890     History of Changes
Other Study ID Numbers: TUD-RELAZA-008, 2006-001040-31 (EudraCT Nr.)
Study First Received: January 15, 2007
Last Updated: July 8, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Technische Universität Dresden:
Acute myeloid leukaemia or Myelodysplastic syndrome

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid
Myelodysplastic Syndromes
Preleukemia
Syndrome
Bone Marrow Diseases
Disease
Hematologic Diseases
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Precancerous Conditions

ClinicalTrials.gov processed this record on October 20, 2014